As of close of business last night, Nurix Therapeutics Inc’s stock clocked out at $14.65, down -5.24% from its previous closing price of $15.46. On the day, 1296561 shares were traded.
Ratios:
To gain a deeper understanding of NRIX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.13.
On March 09, 2023, Barclays started tracking the stock assigning a Overweight rating and target price of $20.
On February 28, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $25.Oppenheimer initiated its Outperform rating on February 28, 2023, with a $25 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 16 ’24 when van Houte Hans sold 6,812 shares for $10.02 per share. The transaction valued at 68,223 led to the insider holds 68,333 shares of the business.
Hansen Gwenn sold 2,334 shares of NRIX for $18,649 on Jan 30 ’24. The Chief Scientific Officer now owns 36,402 shares after completing the transaction at $7.99 per share. On Jan 30 ’24, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 1,760 shares for $7.99 each. As a result, the insider received 14,063 and left with 17,427 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.90 while its Price-to-Book (P/B) ratio in mrq is 4.27.
Stock Price History:
Over the past 52 weeks, NRIX has reached a high of $18.12, while it has fallen to a 52-week low of $4.22.
Shares Statistics:
A total of 48.72M shares are outstanding, with a floating share count of 45.27M. Insiders hold about 7.90% of the company’s shares, while institutions hold 88.65% stake in the company.
Earnings Estimates
As of right now, 11 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.76 for the current quarter, with a high estimate of -$0.49 and a low estimate of -$0.91, while EPS last year was -$0.45. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.65 and low estimates of -$0.9.
Analysts are recommending an EPS of between -$2.69 and -$3.68 for the fiscal current year, implying an average EPS of -$3.12. EPS for the following year is -$3.27, with 10 analysts recommending between -$2.42 and -$4.93.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $89.08M, while the lowest revenue estimate was $50.8M, resulting in an average revenue estimate of $69.06M. In the same quarter a year ago, actual revenue was $76.99M, down -10.30% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $65.05M in the next fiscal year. The high estimate is $90M and the low estimate is $33.35M. The average revenue growth estimate for next year is down -5.80% from the average revenue estimate for this year.
